Rhode Island’s Most Wanted Fugitive Lived as Biotech CMO — Arrested After 21 Years on the Run
Ronald Fischer, convicted of sexual assault, evaded justice for over two decades while living under the alias Richard Graydon as CMO of Immix Biopharma.
/ 3 items
#IMMX↓
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
Morgan Stanley Bullish on Immix Biopharma: Sees $1B+ Opportunity for NXC-201 CAR-T Therapy
Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and $20 price target.